Replies to post #6372 on Biotech Values

[rkrw]

*have the "events" been less than projected?

I thought this PR was going to be an upsizing, perhaps they've been negotiating for a couple of months:

Monday November 22, 3:54 pm ET
Company Reiterates Plan to Extend Enrollment


ATLANTA, Nov. 22 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. (Nasdaq: AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that the original patient enrollment target of 4,000 has been reached for ARISE, a pivotal Phase III clinical trial of AGI-1067 for the treatment of atherosclerosis. As indicated in October, the Company plans to continue enrollment so as to accelerate the accumulation of patient years of exposure on the drug.